AI+Healthcare Has Entered Rapid Commercialization Stage, Tianhong CNI BIOMEDICINE ETF(159859) Surges Over 3% in Morning Trading

NewTimeSpace News - As of 11:00 on January 13, 2026, Biomedical ETF (159859) rose 3.14%, with the latest price at 0.43 yuan. Over a longer timeframe, as of January 12, 2026, Biomedical ETF gained 4.02% over the past week. (The stocks listed above are index constituents only and do not constitute specific recommendations.)

In terms of liquidity, Biomedical ETF recorded an intraday turnover rate of 4.01% and trading volume of 145 million yuan. Over a longer period, as of January 12, its average daily trading volume reached 133 million yuan over the past week, ranking first among comparable funds.

Scale-wise, Biomedical ETF's size grew 54.3343 million yuan over the past week, achieving significant growth and ranking 1st out of 3 comparable funds in new scale increase. (Data source: Wind)

Regarding capital flows, Biomedical ETF posted a latest net capital outflow of 13.3544 million yuan. Over a longer timeframe, it saw net inflows on 11 of the past 19 trading days, totaling 37.1379 million yuan in "capital absorption," with an average daily net inflow of 1.9546 million yuan. (Data source: Wind)

Data shows leveraged funds continue to build positions. Biomedical ETF received net leveraged purchases for three consecutive days, with the highest single-day net purchase reaching 15.3241 million yuan, bringing the latest margin balance to 153 million yuan. (Data source: Wind)

As of January 12, Biomedical ETF's NAV rose 22.56% over the past year, ranking 1st among comparable funds. In terms of return capability, as of January 12, 2026, since its inception, the ETF's highest monthly return was 27.87%, longest consecutive up months was 5, longest consecutive gain was 31.58%, and average return in up months was 5.62%. As of January 12, 2026, its excess return over benchmark since inception was 2.05% annualized.

On drawdowns, as of January 12, 2026, Biomedical ETF's year-to-date maximum drawdown was 0.00%, with a relative benchmark drawdown of 0.01%, the smallest among comparable funds.

In terms of fees, Biomedical ETF charges a management fee of 0.50% and a custody fee of 0.10%, the lowest among comparable funds.

Regarding tracking accuracy, as of January 12, 2026, Biomedical ETF's one-month tracking error was 0.011%, the highest tracking precision among comparable funds.

Biomedical ETF closely tracks the CNI Biomedical Index. The CNI Biomedical Index takes listed companies in the biomedical industry from the Shanghai, Shenzhen, and Beijing exchanges as its sample space, selects the top 30 securities based on comprehensive ranking of market capitalization and liquidity as index constituents, reflects the overall performance of the biomedical industry, and provides the market with index investment instruments for this segment.

Zheshang Securities stated that five ministries issued a document explicitly supporting AI development in healthcare, while OpenAI launched ChatGPT Health and Ant's Afu's monthly active users rapidly climbed to 30 million, reflecting accelerating penetration of AI health services. With resonance between national strategy and market demand, AI+healthcare has entered a rapid commercialization stage.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.